Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Plus: Observe two stunning spirals, see Venus reappear as a morning star, and enjoy the Last Quarter Moon in the sky this ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Here is the weekly road construction report for District 29: ...

The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

MCPS is entering phase two of its boundary study, beginning a period focused on data analysis and initial community ...

The NASA astronauts splashed down on Tuesday in a SpaceX capsule after problems with a Boeing vehicle set in motion a ...

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...

Real Madrid key defender Eder Militao continues to make progress in his recovery after tearing the anterior cruciate ligament ...